Iglesias J, Vassallo AV, Patel VV, et al. - Researchers evaluated an ascorbic acid, thiamine, and hydrocortisone (HAT) treatment bundle for the treatment of septic and septic shock patients admitted to an ICU, via this randomized, double-blinded, placebo-controlled trial performed from February 2018 to June 2019. Resolution of shock and alteration in Sequential Organ Failure Assessment (SOFA) score were evaluated as the primary outcomes. This study involved 137 patients; including 68 in the treatment group and 69 in the comparator group. In the HAT group vs the comparator group, quicker reversal of shock was indicated by the findings. SOFA score did not change statistically significantly between groups 3 (1 - 6) vs 2 (0 - 4). In terms of ICU and hospital mortality, ICU and hospital length of stay, ventilator free days, and procalcitonin clearance, there were no significant disparities between study arms. Overall, a significant decrease in the time to resolution of shock was afforded by the combination of IV ascorbic acid, thiamine, and hydrocortisone.